Does the panic attack activate the hypothalamic-pituitary-adrenal axis?

Anais da Academia Brasileira de Ciencias

Volumn 77, Issue 3, 2005, Pages 477-491

  Graeff, Frederico G ^a   Garcia Leal, Cybele ^a   Del Ben, Cristina M ^a   Guimarães, Francisco S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; Panic attack; Stress hormones

Indexed keywords

EID: 24344458134     PISSN: 00013765     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0001-37652005000300009     Document Type: Article

References (87)

1. ABELSON JL AND NESSE RM. 1990. Cholecystokinin-4 and panic. Arch Gen Psychiatry 47: 395.
2. ABELSON JL, NESSE RM AND VINIK AI. 1994. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry 36: 84-96.
3. ALBUS M, ZAHN TP AND BREIER A. 1992. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur Arch Psychiatry Clin Neurosci 241: 337-344.
4. rd ed., Washington, DC: American Psychiatric Association Press, 756 p.
5. th ed., Washington, DC: American Psychiatric Association Press, 886 p.
6. ANTONI FA. 1993. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14: 76-122.
7. ASNIS GM, WETZLER S, SANDERSON WC, KAHN RS AND VAN PRAAG HM. 1992. Functional interrelationship of serotonin and norepinephrine: cortisol response to MCPP and DMI in patients with panic disorder, patients with depression, and normal controls. Psychiatry Res 43: 65-76.
8. 2 challenge? J Psychopharmacol 17: 252-259.
9. BANDELOW B, WEDEKIND D, PAULS J, BROOCKS A, HAJAK G AND RÜTHER E. 2000. Salivary cortisol in panic attacks. Am J Psychiatry 157: 454-456.
10. BENJAMIN J, NEMETZ H, Fux M, BLEICHMAN I AND AGAM G. 1997. Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder. J Psychiatr Res 31: 489-495.
11. BOURIN M, BAKER GB AND BRADWEJN J. 1998. Neurobiology of panic disorder. J Psychosom Res 44: 163-180.
12. BRADWEJN J, KOSZYCKI D AND METERISSIAN G. 1990. Cholecystokinin- tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35: 83-85.
13. BRADWEJN J, KOSZYCKI D AND SHRIQUI C. 1991. Enhanced sensitivity to cholecystokinin-tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48: 603-610.
14. BROOCKS A ET AL. 2000. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15: 153-161.
15. CAMERON OG, LEE MA, CURTIS GC AND McCANN DS. 1987. Endocrine and physiological changes during "spontaneous" panic attacks. Psychoneuroendocrinol 12: 321-331.
16. CANNON WB. 1914. The emergency function of the adrenal medulla in pain and the major emotions. Am J Physiol 33: 356-372.
17. CARR DB, SHEEHAN DV, SURMAN OS, COLEMAN JH, GREENBLATT DJ, HENINGER GR, JONES KJ, LEVINE PH AND WATKINS WD. 1986. Neuroendocrine cor relates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 143: 483-494.
18. CHARNEY DS, HENINGER GR AND JATLOW PI. 1985. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 42: 233-243.
19. CHARNEY DS, WOODS SW, GOODMAN WK AND HENINGER GR. 1987a. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144: 1030-1036.
20. CHARNEY DS, WOODS SW, GOODMAN WK AND HENINGER GR. 1987b. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacol 92: 14-24.
21. COPLAN JD, GOETZ R, KLEIN DF, PAPP LA, FYER AJ, LIEBOWITZ MR, DAVIES SO AND GORMAN JM. 1998. Plasma cortisol concentrations preceding lactate-induced panic: psychological, biochemical, and physiological correlates. Arch Gen Psychiatry 55: 130-136.
22. DEAKIN JFW AND GRAEFF FG. 1991. 5-HT and mechanisms of defence. J Psychopharmacol 5: 305-315.
23. DEN BOER JA AND WESTENBERG HG. 1990. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 31: 267-278.
24. FLINT AJ, KOSZYCKI D, BRADWEJN J AND VACCARINO FJ. 2000. Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects. Psychoneuroendocrinol 25: 633-647.
25. GARCIA-LEAL C, PARENTE ACBV, DEL-BEN CM, GUIMARÃES FS, MOREIRA AC, ELIAS LLK AND GRAEFF FG. 2004. Anxiety and salivary cortisol in symptomatic and nonsymptomatic panic patients and healthy volunteers performing simulated public speaking. Psychiatry Res 133: 239-252.
26. GERMINE M, GODDARD AW, SHOLOMSKAS DE, WOODS SW, CHARNEY DS AND HENINGER GR. 1994. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54: 115-133.
27. GORMAN JM, ASKANAZI J, LIEBOWITZ MR, PYER AJ, STEIN J, KINNE Y JM AND KLEIN DF. 1984. Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 141: 857-861.
28. GRAEFF FG. 1997. Serotonergic systems. Psychiat Clin N Am 20:723-739.
29. GRAEFF FG. 2004. Serotonin, the periaqueductal gray and panic disorder. Neurosci Biobehav Rev 28: 239-259.
30. GRAEFF FG, PARENTE A, DEL-BEN CM AND GUIMARÃES FS. 2003. Pharmacology of human experimental anxiety. Braz J Med Biol Res 36: 421-432.
31. GRIEZ E AND SCHRUERS K. 1998. Experimental pathophysiology of panic. J Psychosom Res 45: 493-503.
32. GUIMARÃES FS, ZUARDI AW AND GRAEFF FG. 1987. Effect of chlorimipramine and maprotiline on experimental anxiety in humans. J Psychopharmacol 1: 184-192.
33. GURGUIS GN, VITTON BJ AND UHDE TW. 1997. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res 71: 27-39.
34. HAEFELY WE AND HUNKELER W. 1988. The story of flumazenil. Eur J Anesthesiol Suppl 2: 3-13.
35. HETEM LAB. 1995. Addition of d-fenfluramine to benzodiazepines produced a marked improvement in refractory panic disorder - a case report. J Clin Psychopharmacol 16: 77-78.
36. HOLLANDER E, LIEBOWITZ MR, GORMAN JM, COHEN B, FYER A AND KLEIN DF. 1989. Cortisol and sodium lactate-induced panic. Arch Gen Psychiatry 46: 135-140.
37. JUDD FK, APOSTOLOPOULOS M, BURROWS GD AND NORMAN TR. 1994. Serotonergic function in panic disorder: endocrine responses to D-fenfluramine. Prog Neuropsychopharmacol Biol Psychiatry 18: 329-337.
38. KAHN RS, ASNIS GM, WETZLER S AND VAN PRAAG HM. 1988. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacol 96: 360-364.
39. KELLNER M, WIEDEMANN K AND HOLSBOER F. 1992. Atrial natriuretic factor inhibits the CRH-stimulated secretion of ACTH and cortisol in man. Life Sci 50: 1835-1842.
40. KELLNER M, HERZOG L, YASSOURIDIS A, HOLSBOER F AND WIEDEMANN K. 1995. Possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic. Am J Psychiatry 152: 1365-1367.
41. KELLNER M, YASSOURIDIS A, JAHN H AND WIEDEMANN K. 1997. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacol 133: 55-61.
42. KELLNER M, KNAUDT K, JAHN H, HOLSBOER F AND WIEDEMANN K. 1998. Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. J Psychiatry Res 32: 37-48.
43. KHAN S, LIBERZON I AND ABELSON JL. 2004. Effects of propranolol on symptom and endocrine responses to pentagastrin. Psychoneuroendocrinol 29: 1163-1171.
44. KLEIN DF. 1993. False suffocation alarms, spontaneous panics and related conditions. An integrative hypothesis. Arch Gen Psychiatry 50: 306-317.
45. KLEIN E, ZOHAR J, GERACI MF, MURPHY DL AND UHDE TW. 1991. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 30: 973-984.
46. LEVIN AP, DORAN AR, LIEBOWITZ MR, FYER AJ, GORMAN JM, KLEIN DF AND PAUL SM. 1987. Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res 21: 23-32.
47. LIEBOWITZ MR ET AL. 1985. Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 42: 709-719.
48. MADDOCK RJ, CARTER CS AND GIETZEN DW. 1991. Elevated serum lactate associated with panic attacks induced by hyperventilation. Psychiatry Res 38: 301-311.
49. MASON JW. 1975. A historical review of stress. J Hum Stress 1: 6-12.
50. McCANN UD, SLATE SO, GERACI M, ROSCOW-TERRILL D AND UHDE TW. 1997. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls. Neuropsychopharmacol 16: 229-237.
51. MCEWEN BS. 2000. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 886: 172-189.
52. MCNAIR DM, FRANKENTHALER LM, CZERLINSKY T, WHITE TW, SASSON S AND FISHER S. 1982. Simulated public speaking as a model of clinical anxiety. Psychopharmacol 77: 7-10.
53. MCNAUGHTON N AND CORR PJ. 2004. A two-dimensional neuropsychology of defense: fear / anxiety and defensive distance. Neurosci Biobehav Rev 28: 285-305.
54. MORTIMORE C AND ANDERSON IM. 2000. d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. Psychopharmacol 149: 251-258.
55. NUTT DJ, GLUE P, LAWSON C AND WILSON S. 1990. Flumazenil provocation of panic attacks Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 47: 917-925.
56. PESKIND ER, JENSEN CF, PASCUALY M, TSUANG D, COWLEY D, MARTIN DC, WILKINSON CW AND RASKIND MA. 1998. Sodium lactate and hypertonic sodium chloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Biol Psychiatry 44: 1007-1016.
57. PITTS FN AND MCCLURE JN. 1967. Lactate metabolism in anxiety neurosis. N Engl J Med 277: 1329-1336.
58. SASAKI I, AKIYOSHI J, SAKURAI R, TSUTSUMI T, ONO H, YAMADA K AND FUJII I.1996. Carbon dioxide induced panic attack in panic disorder in Japan. Prog Neuropsychopharmacol Biol Psychiatry 20: 1145-1157.
59. SCHENBERG LC, BITTENCOURT AS, SUDRÉ ECM AND VARGAS LC. 2001. Modeling panic attacks. Neurosci Biobehav Rev 25: 647-659.
60. SCHRUERS K, VAN DIENST R, NICOLSON N AND GRIEZ E. 2002. L-5-hydroxytryptophan induced increase in salivary cortisol in panic patients and healthy volunteers. Psychopharmacol 161: 365-369.
61. SEIER FE, KELLNER M, YASSOURIDIS A, HEESE R, STRIAN F AND WIEDEMANN K. 1997. Autonomic reactivity and hormonal secretion in lactate-induced panic attacks. Am J Physiol 272: 2630-2638.
62. SELYEH. 1936. A syndrome produced by diverse nocuous agents. Nature 138: 32.
63. SHLIK J, ALUOJA A, VASAR V, VASAR E, PODAR T AND BRADWEJN J. 1997. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22: 332-340.
64. SINHA SS, COPLAN JD, PINE DS, MARTINEZ JA, KLEIN DF AND GORMAN JM. 1999. Panic induced by carbon dioxide inhalation and lack of hypothalamicpituitary- adrenal axis activation. Psychiatry Res 86: 93-98.
65. SOLYOM L. 1994. Controlling panic attacks with fenfluramine. Am J Psychiatry 151: 621-622.
66. STROHLE A, KELLNER M, YASSOURIDIS A, HOLSBOER F AND WIEDEMANN K. 1998. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155: 610-612.
67. STROHLE A, KELLNER M, HOLSBOER F AND WIEDEMANN K. 1999. Behavioral, neuroendocrine, and cardio-vascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry 45: 321-326.
68. STROHLE A, HOLSBOER F AND RUPPRECHT R. 2000. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacol 22: 251-256.
69. TARGUM SD. 1990. Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 28: 21-34.
70. TARGUM SD. 1992. Cortisol response during different anxiogenic challenges in panic disorder patients. Psychoneuroendocrinol 17: 453-458.
71. TARGUM SD AND MARSHALL LE. 1989. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28: 295-306.
72. VAN DE KAR LD AND BLAIR ML. 1999. Forebrain pathways mediating stress-induced hormone secretion. Front Neuroendocrinol 20: 1-48.
73. VAN DEN HOUT MA AND GRIEZ E. 1984. Panic symptoms after the inhalation of carbon dioxide. Br J Psychiatry 144: 503-507.
74. VAN DUINEN MA, SCHRUERS KR, JAEGERS E, MAES M AND GRIEZ EJ. 2004. Salivary cortisol in panic: are males more vulnerable? Neuro Endocrinol Lett 25: 386-390.
75. VAN MEGEN HJ, WESTENBERG HG, DEN BOER JA, HAIGH RM AND TRAUB M. 1994. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacol 114: 449-455.
76. VAN MEGEN HJ, WESTENBERG HG, DEN BOER JA AND KAHN RS. 1996. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol 6: 187-194.
77. VAN MEGEN HJ, WESTENBERG HG, DEN BOER JA, SLAAP B, VAN ES-RADHAKISHUN F AND PANDE AC. 1997. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacol 129: 243-248.
78. VAN VLIET IM, SLAAP BR, WESTENBERG HG AND DEN BOER JA. 1996. Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur Neuropsychopharmacol 6: 103-110.
79. VARGAS LC, SILVA SR, REIS AM, TUFIK S, CAROBREZ AP AND SCHENBERG LC. 2001. Pharmacological and endocrinological properties of intracranially-induced panic-like behaviors. Soc Neurosci Abstr 27: 858.11.
80. WESTENBERG HG AND DEN BOER JA. 1989. Serotonin function in panic disorder: effect of 1-5-hydroxytryptophan in patients and controls. Psychopharmacol 98: 283-285.
81. WETZLER S, ASNIS GM, DELECUONA JM AND KALUS O. 1996. Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 64: 77-82.
82. WOODS SW, CHARNEY DS, MCPHERSON CA, GRADMAN AH AND HENINGER GR. 1987. Situational panic attacks. Behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 44: 365-375.
83. WOODS SW, CHARNEY DS, GOODMAN WK AND HENINGER GR. 1988. Carbon dioxide induced anxiety: behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry 45: 43-52.
84. WOODS SW, CHARNEY DS, SILVER JM, KRYSTAL JH AND HENINGER GR. 1991. Behavioral, biochemical and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 36: 115-127.
85. WORLD HEALTH ORGANIZATION. 1992. The ICD-10 classification of mental and behavioral disorders. Clinical descriptions and diagnostic guidelines. Geneva, 351 p.
86. ZWANZGER P, BAGHAI TC, SCHUELE C, STROHLE A, PADBERG F, KATHMANN N, SCHWARZ M, MOLLER HJ AND RUPPRECHT R. 2001. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacol 25: 699-703.
87. ZWANZGER P, ESER D, AICHER S, SCHULE C, BAGHAI TC, PADBERG F, ELLA R, MOLLER HJ AND RUPPRECHT R. 2003. Effects of alprazolam on cholecystokinin- tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacol 28: 979-984.